Innovative Aseptic Micro-Connector Launch for CGT Applications
Innovative Aseptic Micro-Connector Launch for CGT Applications
CPC (Colder Products Company), a part of Dover Corporation and recognized for its leading role in connection technologies in biopharmaceutical processing, has recently unveiled an advanced aseptic micro-connector specifically designed for integration into freeze cassettes utilized in cell and gene therapy (CGT) processing. This revolutionary product aims to redefine standards for cryopreservation, a crucial step that freezes biological materials used in CGT, preventing functional loss during shipment and storage.
The Importance of Cryopreservation
Cryopreservation plays a vital role in the effectiveness of cell and gene therapies. As therapies are transported to patients, the risk of degradation of biological materials is significant. By enabling storage at ultralow temperatures, this technique safeguards the integrity of these materials until they reach their destinations.
Introducing the MicroCNX ULT Series
The new MicroCNX ULT Series is designed to meet the demanding needs of modern cell therapy processes, capable of withstanding temperatures as low as -190°C. According to Troy Ostreng, Senior Product Manager for CPC's biopharmaceutical division, the micro-connector not only supports sterility but is also compact enough to seamlessly fit into CGT freeze cassettes, offering both practicality and efficiency throughout the therapy development process.
Features of the MicroCNX ULT Connectors
The MicroCNX ULT connectors revolutionize how sterile connections are made in small-format systems used in cell and gene therapy applications. Their construction ensures compatibility with the aggressive solvents often employed in cryopreservation, such as dimethyl sulfoxide (DMSO), and with a variety of commonly used tubing types including polyvinyl chloride (PVC).
Building on Proven Success
CPC’s introduction of the MicroCNX ULT Series builds upon their groundbreaking innovations, including the MicroCNX Series, which is the smallest connector viable for creating closed sterile connections with minimal volumes. This alternative to tube welding has set a new standard in the industry.
Recent Product Introductions
In a related move, CPC recently launched MicroCNX Luers, which offer enhanced connectivity options for manufacturers needing to create sterile connections outside of biosafety cabinets. This flexibility is appreciated by those in the industry, promoting comprehensive solutions tailored to specific operational needs.
CPC's Vision for the Future
As a leader in aseptic connection technologies, CPC is committed to supporting its customers from initial development stages through to commercialization. Ostreng emphasizes that the breadth of their aseptic connector portfolio positions CPC to adapt to the evolving landscape of cell therapy, gene therapy, and biopharmaceutical manufacturing globally.
For further details on the MicroCNX series connectors and the innovative solutions that CPC provides, visit their website to explore the full range of products and services tailored to enhance biopharmaceutical processing operations.
About CPC
CPC (Colder Products Company) specializes in single-use connection technology and offers a wide array of connectors for biopharmaceutical manufacturing processes. Their products are designed to maintain sterility and media integrity while ensuring efficient production yields. Notably, the AseptiQuik® connectors facilitate quick sterile connections, even in challenging environments.
About Dover Corporation
Dover Corporation is a well-established diversified global manufacturer delivering innovative solutions across several sectors with an annual revenue exceeding $8 billion. With approximately 25,000 employees dedicated to redefining industry standards, Dover’s operational agility enables them to meet diverse customer needs efficiently. The company's stock trades on the New York Stock Exchange under the ticker symbol DOV.
Frequently Asked Questions
What is the purpose of the MicroCNX ULT Series?
The MicroCNX ULT Series is designed to support sterile connections in cell and gene therapy processes, ensuring compatibility with extreme temperatures and harsh chemicals.
How does cryopreservation affect cell therapy?
Cryopreservation minimizes the risk of functional loss in biological materials required for cell therapy during transportation and storage.
Who is the parent company of CPC?
CPC is a part of Dover Corporation, a global manufacturing leader.
What advancements does the MicroCNX series offer?
The MicroCNX series offers a compact design that withstands low temperatures and is chemically compatible with substances used in cryopreservation.
How does CPC support its customers?
CPC aims to provide comprehensive solutions from development to commercial stages, helping customers simplify the process of creating sterile connections.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.